TY - JOUR
T1 - Randomized comparison of Ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - Design and rationale of the intracoronary stenting and antithrombotic regimen
T2 - Rapid early action for coronary treatment (ISAR-REACT) 5 trial
AU - Schulz, Stefanie
AU - Angiolillo, Dominick J.
AU - Antoniucci, David
AU - Bernlochner, Isabell
AU - Hamm, Christian
AU - Jaitner, Juliane
AU - Laugwitz, Karl Ludwig
AU - Mayer, Katharina
AU - Von Merzljak, Barbara
AU - Morath, Tanja
AU - Neumann, Franz Josef
AU - Richardt, Gert
AU - Ruf, Judith
AU - Schömig, Gisela
AU - Schühlen, Helmut
AU - Schunkert, Heribert
AU - Kastrati, Adnan
N1 - Funding Information:
Conflict of interest Dominick J. Angiolillo reports receiving payment (a) as consulting fee or honorarium from Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Merck, Evolva, Abbott Vascular and PLx Pharma; (b) for participation in review activities from Johnson & Johnson, St. Jude, and Sunovion; institutional payments for grants from Bristol Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Evolva; and for other financial relationships with Esther and King Biomedical Research Grant. David Antoniucci reports receiving consulting fee or honorarium from AstraZeneca and Eli Lilly, payment for lectures including service on speakers bureaus for Bayer, and travel/accommodations/meeting expenses unrelated to activities listed from Terumo. Adnan Kastrati reports receiving lecture fees from Abbott, Biotronik and The Medicines; from advisory board meetings for AstraZeneca, MSD, and St. Jude Medical; and from event adjudication for Biosensors. Franz-Josef Neumann reports consultancy, grants/grant pending, and payment for lectures including service on speakers bureaus from Eli Lilly, Daiichi Sankyo, and AstraZeneca. Helmut Schühlen reports consultancy and payment for lectures including service on speakers bureaus from Lilly and Daiichi Sankyo and grants/grants pending from AstraZeneca. The other coauthors have reported no conflicts of interest.
PY - 2014/2
Y1 - 2014/2
N2 - In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.
AB - In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.
KW - Acute coronary syndrome
KW - PCI
KW - Prasugrel
KW - Ticagrelor
UR - http://www.scopus.com/inward/record.url?scp=84896708052&partnerID=8YFLogxK
U2 - 10.1007/s12265-013-9527-3
DO - 10.1007/s12265-013-9527-3
M3 - Article
C2 - 24371012
AN - SCOPUS:84896708052
SN - 1937-5387
VL - 7
SP - 91
EP - 100
JO - Journal of Cardiovascular Translational Research
JF - Journal of Cardiovascular Translational Research
IS - 1
ER -